Zuranolone: First Approval

Zuranolone: First Approval

Zuranolone (ZURZUVAE ™ ) is an oral neuroactive steroid and a positive allosteric modulator of the gamma aminobutyric acid A (GABA A ) receptor being developed by Sage Therapeutics and Biogen for the treatment of mood disorders. In August 2023, zuranolone received its first approval in the USA for t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Drugs (New York, N.Y.) N.Y.), 2023-11, Vol.83 (16), p.1559-1567
1. Verfasser: Heo, Young-A
Format: Artikel
Sprache:eng
Schlagworte:
AdisInsight Report
Agreements
Allosteric properties
Drug dosages
Emotional disorders
FDA approval
Internal Medicine
Medicine
Medicine & Public Health
Mental depression
Metabolites
Mood disorders
Oral administration
Pharmacokinetics
Pharmacology/Toxicology
Pharmacotherapy
Postpartum depression
Steroids
Substance abuse treatment
γ-Aminobutyric acid A receptors
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Zuranolone (ZURZUVAE ™ ) is an oral neuroactive steroid and a positive allosteric modulator of the gamma aminobutyric acid A (GABA A ) receptor being developed by Sage Therapeutics and Biogen for the treatment of mood disorders. In August 2023, zuranolone received its first approval in the USA for the treatment of adults with postpartum depression [pending scheduling by the US Drug Enforcement Administration (DEA)]. This article summarizes the milestones in the development of zuranolone leading to this first approval.
ISSN:0012-6667
1179-1950
DOI:10.1007/s40265-023-01953-x